Trial Profile
A retrospective study comparing signal intensity changes using gadolinium-based contrast agent gadobenate dimeglumine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2016
Price :
$35
*
At a glance
- Drugs Gadobenic acid (Primary)
- Indications Brain disorders
- Focus Diagnostic use
- 28 Sep 2016 New trial record